Clinical trial shows promise for new treatment in patients with leptomeningeal disease

Researchers at Moffitt Cancer Center have reported encouraging results from a phase 1B clinical trial showing that the immunotherapy drug avelumab, when combined with whole brain radiotherapy, may provide a safe and effective treatment option for patients with leptomeningeal disease, one of the most aggressive and difficult-to-treat complications of advanced cancer.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup